Skip to main content
Opthea Ltd logo

Opthea Ltd — Investor Relations & Filings

Ticker · OPT ISIN · US68386J2087 LEI · 549300Q5FMFDLP46SF83 ASX Manufacturing
Open in API
Filings indexed 1,390 across all filing types
Latest filing 2011-10-09 Capital/Financing Update
Country AU Australia
Listing ASX OPT

About Opthea Ltd

https://opthea.com/

Opthea is a clinical-stage biopharmaceutical company focused on developing novel therapies for vision-threatening retinal diseases, particularly wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). The company's lead product candidate, sozinibercept, is a first-in-class biologic 'trap' inhibitor targeting Vascular Endothelial Growth Factors C and D (VEGF-C and VEGF-D). Sozinibercept is being developed for administration in combination with standard-of-care anti-VEGF-A therapies. This dual-pathway inhibition aims to deliver superior visual outcomes by more comprehensively blocking the mechanisms that contribute to disease progression, addressing the limitations of current treatments that only target VEGF-A. The therapy is being evaluated in late-stage pivotal clinical trials for wet AMD.

Recent filings

Filing Released Lang Actions
Clinical validation study of CUP Test commences 5 pages 62.3KB
Capital/Financing Update Classification · 95% confidence The document is an ASX and media release dated 9 October 2011 from Circadian Technologies Limited. It announces the commencement of a clinical validation study for a cancer diagnostic test developed in collaboration with Healthscope and other partners. The content focuses on the development progress, commercial launch expectations, partnerships, and background information about the companies and the technology. There are no financial statements, regulatory certifications, voting results, or management changes. The document is a corporate announcement about a product development milestone and commercial plans, typical of a Capital/Financing Update or general corporate update. It is not an earnings release, annual or interim report, nor a regulatory filing or legal proceeding. Given the nature of the announcement about a development milestone and commercial launch plans, the most appropriate classification is Capital/Financing Update (CAP). The document length is substantial and contains detailed information about the product and commercial arrangements, supporting a high confidence in this classification.
2011-10-09 English
Retirements from Circadian Board of Directors 2 pages 31.1KB
Board/Management Information Classification · 100% confidence The document is an ASX and media release dated 3 October 2011 announcing retirements from the Circadian Board of Directors. It details the departure dates and statements from the retiring directors, as well as comments from the Chairman. The content focuses exclusively on changes in the company's board membership and does not include financial data, earnings, or other report types. There is no indication that this is a full report or a regulatory filing beyond the announcement. Therefore, the document fits the category of Board/Management Information (MANG), which covers announcements of changes in the company's board of directors or senior management.
2011-10-02 English
Circadian files IND with FDA for VGX-100 3 pages 55.8KB
Capital/Financing Update Classification · 95% confidence The document is an ASX and media release announcing that Circadian Technologies Limited has filed an Investigational New Drug (IND) application with the FDA for VGX-100, a drug candidate for cancer treatment. The text describes the IND filing as a milestone, explains the IND process, and provides background on the company's drug pipeline and investment risks. There are no financial statements, quarterly or annual results, or detailed financial data. The document is a corporate announcement about a regulatory filing related to clinical trial initiation, not a financial report or earnings release. It is not a report publication announcement since it contains substantive information about the IND filing and the company's development plans. The best fitting category is Capital/Financing Update (CAP) because the IND filing is a significant development milestone related to the company's clinical development and potential future capital needs, and such filings are typically classified under CAP for biotech companies. Confidence is high given the clear nature of the announcement and its content.
2011-09-29 English
Open Briefing - CEO on FY12 Outlook and VGX-100 Progress 5 pages 379.6KB
Investor Presentation Classification · 95% confidence The document is an ASX announcement titled 'CEO on FY12 Outlook and VGX-100 Progress' dated 15 September 2011. It is an Open Briefing interview with the CEO & MD discussing the company's drug development progress, financial outlook, R&D expenses, and upcoming clinical trials. The content includes detailed discussion of business strategy, financial expectations, and operational updates rather than a formal financial report or earnings release. It is not a transcript of a conference call but a prepared Q&A style briefing. The document length is over 13,000 characters, indicating substantive content. The nature of the document aligns with an Investor Presentation (IP) as it provides detailed information for investors about financials, strategy, and market position. It is not an earnings release (ER) because it contains more detailed discussion and outlook rather than just key financial highlights. It is not an Annual Report or Interim Report as it lacks comprehensive financial statements. Therefore, the best classification is Investor Presentation (IP).
2011-09-14 English
VGX-100 potential new therapy for Dry Eye Disease 4 pages 45.9KB
Regulatory Filings Classification · 95% confidence The document is an ASX and media release dated 13 September 2011 from Circadian Technologies Limited. It announces the publication of scientific data regarding VGX-100 as a potential new therapy for Dry Eye Disease. The content focuses on the scientific findings, therapeutic potential, and company background, but does not contain financial statements, regulatory certifications, or detailed financial analysis. It is a corporate announcement about scientific and clinical development progress rather than a financial report or regulatory filing. There is no indication that this is a transcript, management report, or capital update. The document is a press release announcing scientific data publication and company news, which fits best under Regulatory Filings (RNS) as a general regulatory announcement and corporate update that does not fit other specific categories.
2011-09-12 English
Key appointment in clinical trials management 3 pages 33.5KB
Board/Management Information Classification · 95% confidence The document is an ASX and media release dated 12 September 2011 announcing the appointment of Dr Ian Leitch to a key clinical trials management position at Circadian Technologies Limited. It focuses on the appointment details, Dr Leitch's background, the company's pipeline, and investment risks. There are no financial statements, regulatory certifications, voting results, or report attachments. The content is a corporate announcement about a management appointment rather than a financial report, regulatory filing, or other specific report types. Therefore, the document fits best under Board/Management Information (MANG), which covers announcements of changes in senior management.
2011-09-11 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.